Problèmes actuels dans la prise en charge de l’adénocarcinome rénal sporadique à cellules non claires
Résumé
L’adénocarcinome rénal (AR) est le 10e type de cancer le plus fréquent au Canada. De nombreux progrès réalisés au cours de la dernière décennie dans la prise en charge de l’AR ont permis d’améliorer les résultats, même si ceux‑ci concernent principalement les quelque 80 % de patients atteints d’un adénocarcinome rénal à cellules claires (ARcc). Les 20 % autres cas sont classés dans la catégorie des adénocarcinomes à cellules non claires (ARcnc) et représentent un groupe de maladies biologiquement et cliniquement hétérogènes qui sont des entités rares. Historiquement, le traitement de l’ARcnc était similaire à celui des tumeurs à cellules claires. L’ARcnc localisé offre de meilleurs résultats que celui à cellules claires; mais la survie de l’ARcnc métastatique est inférieure à celle de l’ARcc (la survie globale [SG] médiane de l’ARcnc métastatique est de 39,2 mois, contre 81,1 mois pour l’ARcc).
Ces données ont suscité l’intérêt de la communauté scientifique et des patients atteints d’AR pour améliorer davantage les résultats des patients atteints d’AR à cellules non claires. Cet article décrira la prise en charge actuelle des patients atteints d’ARcnc et abordera les domaines d’intérêt futurs dans ce domaine.
Références
Graham J, Ahmad AE, Basappa NS, Bernhard JC, Bhindi B, Bossé D, et al. 2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma. Can Urol Assoc J. 2024;18(11):E371-e86.
Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun. 2020;23:100172.
Urman D, Deshler L, Weise N, Shabaik A, Derweesh I, Bagrodia A, et al. Outcomes of patients with advanced renal cell carcinoma with non-clear cell histology treated with systemic therapy. Clin Genitourin Cancer. 2023;21(6):660-8.e1.
Goswami PR, Singh G, Patel T, Dave R. The WHO 2022 Classification of renal neoplasms (5th Edition): Salient updates. Cureus. 2024;16(4):e58470.
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458-68.
Cardenas LM, Sigurdson S, Wallis CJD, Lalani A-K, Swaminath A. Advances in the management of renal cell carcinoma. CMAJ. 2024;196(7):E235-E40.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(9):1133-44.
Gulati S, Tangen C, Ryan CW, Vaishampayan UN, Shuch BM, Barata PC, et al. Adjuvant everolimus in non–clear cell renal cell carcinoma: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(8):e2425288-e.
Allaf ME, Kim S-E, Master V, McDermott DF, Harshman LC, Cole SM, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 2024;25(8):1038-52.
Pal SK, Tangen C, Thompson IM, Jr., Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695-703.
Barata P, Tangen C, Plets M, Thompson IM, Narayan V, George DJ, et al. Final Overall survival analysis of S1500: a randomized, phase ii study comparing sunitinib with cabozantinib, crizotinib, and savolitinib in advanced papillary renal cell carcinoma. J Clin Oncol. 2024;42(33):3911-6.
Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023;24(8):881-91.
Voss MH, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. First-line pembrolizumab plus lenvatinib for advanced non–clear-cell renal cell carcinoma: updated results from the phase 2 KEYNOTE-B61 trial. Eur Urol. 2025.
McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029-39.
Lee C-H, Voss MH, Carlo MI, Chen Y-B, Zucker M, Knezevic A, et al. Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol. 2022;40(21):2333-41.
Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer. 2022;10(2).
Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, et al. Immune-based combinations in intermediate-/poor-risk patients with non–clear cell renal cell carcinoma: results from the ARON-1 study. Eur Urol Focus. 2025.
Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, et al. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. Ann Oncol. 2025;36(7):796-806.
Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, et al. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol. 2025;8(2):315-23.
Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, et al. Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. Front Oncol. 2022;12:970199.
Oudard S, Banu, E, Vieillefond, A, Fournier, L, Priou, F, Medioni, J, Culine, S. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Genitales) Study. J Urol. 2007;177:1698-702.
Srinivasan R, Gurram S, Singer EA, Sidana A, Al Harthy M, Ball MW, et al. Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer. N Engl J Med. 2025;392(23):2346-56.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, et al. Genomic Profiling and Response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma. Eur Urol. 2023;83(2):163-72.
Kong W, Wu G, Xu Y, Wang Z, Zhang J. Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study. J Clin Oncol. 2025;43(5_suppl):443-.
Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, et al. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials. 2021;108:106482.
Choueiri TK, Xu W, Poole L, Telaranta-Keerie A, Hartmaier R, Powles T. SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC). J Clin Oncol. 2022;40(16_suppl):TPS4601-TPS.
Maughan BL, Plets M, Pal SK, Ged Y, Tangen C, Vaishampayan UN, et al. SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC). J Clin Oncol. 2024;42(4_suppl):TPS493-TPS.
Nepali PR, Eraky A, Okhawere KE, Dogra N, Mehrazin R, Badani K, et al. Molecular and therapeutic landscape of non-clear cell renal carcinoma. Nat Rev Urol. 2025.
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian Oncology Today 2025
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
